Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-26), Abbott Laboratories's Intrinsic Value: Projected FCF is CHF49.25. The stock price of Abbott Laboratories is CHF93.00. Therefore, Abbott Laboratories's Price-to-Intrinsic-Value-Projected-FCF of today is 1.9.
The historical rank and industry rank for Abbott Laboratories's Intrinsic Value: Projected FCF or its related term are showing as below:
XSWX:ABT'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.02 Med: 1.9 Max: 2.87
Current: 1.89
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Abbott Laboratories was 2.87. The lowest was 1.02. And the median was 1.90.
XSWX:ABT's Price-to-Projected-FCF is ranked worse than 60% of 410
companies
in the Medical Devices & Instruments industry
Industry Median: 1.5
vs XSWX:ABT: 1.89
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Abbott Laboratories's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
93.00
/
52.512072906907
=
1.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories Intrinsic Value: Projected FCF Related Terms
Abbott Laboratories Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABT vs SYK, MDT, BSX: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Abbott Laboratories's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of CHF49.25 mean?
Abbott Laboratories (XSWX:ABT) has a Intrinsic Value: Projected FCF of CHF49.25 as of Aug. 26, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Abbott Laboratories and its competitors. According to the industry distribution chart, Abbott Laboratories ranks #246 out of 410 companies in the Medical Devices & Instruments industry, placing it in the top 60%.
Is Abbott Laboratories' Intrinsic Value: Projected FCF too high?
Abbott Laboratories' current Intrinsic Value: Projected FCF is CHF49.25. Based on the distribution chart, Abbott Laboratories ranks #246 out of 410 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Intrinsic Value: Projected FCF compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #246 out of 410 companies for Intrinsic Value: Projected FCF. This places Abbott Laboratories in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Intrinsic Value: Projected FCF is CHF49.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Intrinsic Value: Projected FCF of CHF49.25. The stock's GF Value™ is CHF106.15, compared to a current price of CHF93.00 — trading 12.4% below its estimated fair value. The current Intrinsic Value: Projected FCF is CHF49.25. Abbott Laboratories' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Intrinsic Value: Projected FCF is CHF49.25 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF93.00 is trading 12.4% below its estimated GF Value™ of CHF106.15.
Key valuation signals for XSWX:ABT:
Intrinsic Value: Projected FCF: CHF49.25
GF Value™: CHF106.15 vs. price of CHF93.00 (12.4% below fair value)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
78GF Score
Get the complete analysis for XSWX:ABT
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
